Crypta Devarakonda's questions to Bristol-Myers Squibb Co (BMY) leadership • Q3 2024
Question
Crypta Devarakonda asked about the HFpEF program, specifically how Phase II data from mavacamten translates to the new lead asset MYK-224, and inquired about the market size and development timelines.
Answer
Head of Global Drug Development Samit Hirawat explained the mavacamten study provided confidence to advance MYK-224, with Phase II data expected in the next couple of years and Phase III readouts in the early part of the next decade. Chief Commercialization Officer Adam Lenkowsky added that HFpEF is a significant opportunity, affecting ~3 million people in the U.S. in a market expected to nearly double by 2032.